世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米、欧州、アジア太平洋地域の大型分子バイオアナリシス試験サービス市場調査レポート：2030年までの予測


North America, Europe, and Asia-Pacific Large Molecule Bioanalysis Testing Services Market Research Report Forecast to 2030

北米、欧州、アジア太平洋地域の高分子バイオアナリシス試験サービス市場調査レポート：2030年までの予測 市場概要 北米、欧州、アジア太平洋地域の高分子バイオ分析検査サービス市場は、ハイテクで信頼性の高... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Market Research Future
マーケットリサーチフューチャー (MRFR) 		2023年11月1日 US$5,250
ライセンス・価格情報
注文方法はこちら 		144 英語

　

サマリー

北米、欧州、アジア太平洋地域の高分子バイオアナリシス試験サービス市場調査レポート：2030年までの予測
市場概要
北米、欧州、アジア太平洋地域の高分子バイオ分析検査サービス市場は、ハイテクで信頼性の高い高分子バイオ分析検査サービスに対する需要の高まり、ラボ検査サービスのアウトソーシング傾向の高まり、臨床試験件数の増加などにより拡大しています。しかし、適切な分析技術を開発することの難しさが、北米、欧州、アジア太平洋地域の高分子バイオ分析検査サービス市場の成長を制限している。さらに、慢性疾患の有病率の増加は、北米、欧州、アジア太平洋地域の高分子バイオアナリシス検査サービス市場に有利な成長機会をもたらすと期待されている。
タンパク質や抗体などの生物学的サンプルに含まれる高分子の濃度は、高分子バイオ分析検査サービスを用いて測定される。高分子は医薬品開発に頻繁に利用され、バイオ分析検査はこれらの医薬品の安全性と有効性を保証するために必要とされる。
市場の成長が期待される背景には、ハイテクで信頼性の高い高分子バイオ分析検査サービスに対する需要の増加、ラボ検査サービスのアウトソーシング傾向の高まり、バイオ医薬品部門における研究開発費の増加がある。しかし、適切な分析技術の開発における課題も市場の足かせとなっている。とはいえ、慢性疾患の罹患率の増加は、北米、欧州、アジア太平洋地域の高分子バイオ分析試験サービス市場で事業を展開する企業にとって有利な機会を創出すると予想される。
市場セグメンテーション
試験タイプに基づき、高分子バイオアナリシス試験市場は薬物動態（PK）試験、薬力学試験、生物学的同等性試験、免疫原性試験、バイオマーカー試験、その他に区分される。治療領域に基づくと、高分子バイオアナリシス試験市場は、腫瘍学、感染症、心血管疾患、神経学、自己免疫疾患、その他に区分される。検査タイプ別に見ると、高分子バイオアナリシス検査市場は、製薬・バイオ医薬品企業、開発・製造受託機関（CDMO）、開発業務受託機関（CRO）、学術・研究機関、その他に区分される。
地域別分析
地域別に見ると、高分子バイオアナリシス試験サービス市場は北米、欧州、アジア太平洋に区分される。北米は2022年に45.29%の最大市場シェアを占め、予測期間中のCAGRは8.70%で2030年には約14億9,885万ドルに達すると予測されている。しかし、アジア太平洋地域は2030年までに11.52%という最高のCAGRを記録すると予測されている。
主要プレイヤー
Laboratory Corporation of America Holdings（米国）、ICON plc（アイルランド）、SGS Société Générale de Surveillance SA（スイス）、WuXi AppTec（中国）、Charles River Laboratories（米国）。市場成長に貢献しているその他の主要企業には、Eurofins Scientific（ルクセンブルク）、QPS Holdings（米国）、BioTechne（米国）、PPD, Inc（米国）、BioAgilytix Labs（米国）、Smithers（米国）、Meso Scale Diagnostic, LLC（米国）、シミックホールディングス株式会社（日本）などがある。




ページTOPに戻る


目次

目次
1 エグゼクティブ・サマリー 17
1.1 概要
2 市場紹介 19
2.1 定義 19
2.2 調査範囲 19
2.3 調査目的 19
2.4 市場構造 20
2.5 前提条件と限界 20
3 調査方法 21
3.1 データマイニング 21
3.2 二次調査 22
3.3 一次調査 23
3.4 主要回答者の内訳 24
3.5 予測手法 25
3.6 市場規模推定のための調査手法 26
3.6.1 ボトムアップアプローチ 26
3.6.2 トップダウンアプローチ 27
3.7 データの三角測量 27
3.8 検証 28
4 市場ダイナミクス 29
4.1 概要
4.2 推進要因 30
4.2.1 ハイテクで信頼性の高い高分子バイオ分析試験サービスに対する需要の増加 30
4.2.2 ラボ検査サービスのアウトソーシング傾向の高まり 30
4.30 2.3 バイオ医薬品部門における研究開発費の増加 30
4.3 阻害要因 31
4.3.1 適切な分析技術の開発における課題 31
4.4 機会 32
4.4.1 慢性疾患の罹患率の増加 32
5 市場要因分析 33
5.1 バリューチェーン分析 33
5.1.1 顧客獲得（購入前の問い合わせ） 33
5.1.2 サービスのカスタマイズ 34
5.1.3 顧客の購入サポート 34
5.1.4 顧客対応と購入後のサポート 34
5.2 ポーターの5力モデル 35
5.2.1 新規参入の脅威 36
5.2.2 サプライヤーの交渉力 36
5.2.3 代替品の脅威 36
5.2.4 買い手の交渉力 36
5.2.5 ライバルの激しさ 36
5.3 Covid-19が北米、欧州、アジア太平洋地域の高分子バイオ分析試験サービス市場に与える影響 37
5.3.1 サプライチェーンへの影響 37
5.3.2 サービスプロバイダーへの影響
6 北米、欧州、アジア太平洋地域の高分子バイオアナリシス検査サービス市場：検査タイプ別 38
6.1 概要 38
6.2 薬物動態（PK）試験 40
6.3 薬力学的（PD）試験 41
6.4 生物学的同等性試験 41
6.5 バイオマーカー試験 42
6.6 免疫原性試験
6.7 その他 43
7 北米、欧州、アジア太平洋地域の高分子バイオアナリシス試験サービス市場：治療領域別 44
7.1 概要
7.2 臨床検査 46
7.3 感染症 47
7.4 循環器疾患 47
7.5 神経系 47
7.6 自己免疫疾患 48
7.7 その他 48
8 北米、欧州、アジア太平洋地域の高分子バイオアナリシス検査サービス市場：エンドユーザー別 49
8.1 概要 49
8.2 製薬会社およびバイオ製薬会社 51
8.3 開発・製造受託機関（CDMOS） 52
8.4 受託研究機関（CRO） 52
8.5 学術・研究機関 53
8.6 その他
9 北米、欧州、アジア太平洋地域の高分子バイオ分析試験サービス市場（地域別） 54
9.1 概要
9.2 北米 58
9.2.1 米国
9.2.2 カナダ 63
9.3 欧州 65
9.3.1 ドイツ 69
9.3.2 フランス 71
9.3.3 イギリス 72
9.3.4 イタリア 74
9.3.5 スペイン 75
9.3.6 スイス 77
9.3.7 オランダ 78
9.3.8 ベルギー 80
9.3.9 スイス 81
9.3.10 ノルウェー 83
9.3.11 デンマーク 84
9.3.12 アイルランド 86
9.3.13 フィンランド 87
9.3.14 その他のヨーロッパ 89
9.4 アジア太平洋 91
9.4.1 中国 95
9.4.2 インド 96
9.4.3 日本 98
9.4.4 韓国 99
9.4.5 オーストラリア 101
9.4.6 その他のアジア太平洋地域 102
10 競争環境 104
10.1 概要 104
10.2 競合のベンチマーク 106
10.3 大分子バイオアナリシスのトップ企業（カテゴリー別） 106
10.3.1 高分子バイオ分析のトップ企業：製薬企業別 106
10.3.2 高分子バイオ分析のトップ企業：CDMO別 107
10.3.3 高分子バイオ分析の上位企業：医薬品別 107
10.3.4 高分子バイオ分析のトップ企業：学術研究機関別 108
10.4 北米、欧州、アジア太平洋地域の高分子バイオアナリシス検査サービス市場における主要成長戦略 108
10.5 北米、欧州、アジア太平洋地域の高分子バイオアナリシス検査サービス市場における開発数上位企業 109
10.6 主要開発分析 110
10.7 主要開発と成長戦略 110
10.7.1 事業拡大 110
10.8 主要企業の財務 111
10.8.1 売上高（百万米ドル）、2022年 111
10.8.2 研究開発費（百万米ドル）、2022年 111
11 会社プロファイル 112
11.1 ラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス 112
11.1.1 会社概要 112
11.1.2 財務概要 113
11.1.3 提供サービス 113
11.1.4 主要な開発 114
11.1.5 swot分析 114
11.1.6 主要戦略 114
11.2 PPD INC 115
11.2.1 会社概要 115
11.2.2 財務概要 115
11.2.3 提供サービス 115
11.2.4 主要な開発 115
11.2.5 swot分析 116
11.2.6 主要戦略 116
11.3 ユーロフィンズ・サイエンティフィック 117
11.3.1 会社概要 117
11.3.2 財務概要 118
11.3.3 提供サービス 118
11.3.4 主要な開発 119
11.3.5 swot分析 119
11.3.6 主要戦略 119
11.4 無錫アプテック 120
11.4.1 会社概要 120
11.4.2 財務概要 121
11.4.3 提供サービス 122
11.4.4 主要開発 122
11.4.5 主要戦略 122
11.5 QPSホールディングス 123
11.5.1 会社概要 123
11.5.2 財務概要 123
11.5.3 提供サービス 123
11.5.4 主要な事業展開 123
11.5.5 主要戦略 123
11.6 バイオテクネ 125
11.6.1 会社概要 125
11.6.2 財務概要 126
11.6.3 提供サービス 126
11.6.4 主要な事業展開 127
11.6.5 主要戦略 127
11.7 アイコンPLC 128
11.7.1 会社概要 128
11.7.2 財務概要 129
11.7.3 提供サービス 129
11.7.4 主要な開発 129
11.7.5 swot分析 130
11.7.6 主要戦略 130
11.8 チャールズ・リバー・ラボラトリーズ 131
11.8.1 会社概要 131
11.8.2 財務概要 132
11.8.3 提供サービス 133
11.8.4 主要な開発 133
11.8.5 swot分析 134
11.8.6 主要戦略 134
11.9 SGS ソシエテ ジェネラル ドゥ サーベイランス SA 135
11.9.1 会社概要 135
11.9.2 財務概要 135
11.9.3 提供製品・サービス 136
11.9.4 主要事業展開 136
11.9.5 主要戦略 136
11.10 バイオアジリティックス・ラボ 137
11.10.1 会社概要 137
11.10.2 財務概要 137
11.10.3 提供サービス 137
11.10.4 主要開発分野 137
11.10.5 主要戦略 137
11.11 スミザーズ 138
11.11.1 会社概要 138
11.11.2 財務分析 138
11.11.3 提供サービス 138
11.11.4 主要な事業展開 138
11.11.5 主要戦略 138
11.12 メソ・スケール・ダイアグノスティックス 139
11.12.1 会社概要 139
11.12.2 財務分析 139
11.12.3 提供サービス 139
11.12.4 主要開発品目 139
11.12.5 主要戦略 139
11.13 セミックホールディングス(株) 140
11.13.1 会社概要 140
11.13.2 財務概要 140
11.13.3 提供サービス 141
11.13.4 主要事業展開 141
11.13.5 主要戦略 141
12 参考文献 142
12.1 関連レポート 143

ページTOPに戻る



図表リスト

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 20
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23
TABLE 3 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 39
TABLE 4 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR PHARMACOKINETIC (PK) STUDIES, BY REGION 2019–2032 (USD MILLION) 40
TABLE 5 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR PHARMACODYNAMIC (PD) STUDIES, BY REGION 2019–2032 (USD MILLION) 41
TABLE 6 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR BIOEQUIVALENCE STUDIES, BY REGION 2019–2032 (USD MILLION) 41
TABLE 7 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR BIOMARKER TESTING, BY REGION 2019–2032 (USD MILLION) 42
TABLE 8 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR IMMUNOGENICITY TESTING, BY REGION 2019–2032 (USD MILLION) 42
TABLE 9 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR OTHERS, BY REGION 2019–2032 (USD MILLION) 43
TABLE 10 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2032 (USD MILLION) 45
TABLE 11 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR ONCOLOGY, BY REGION 2019–2032 (USD MILLION) 46
TABLE 12 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR INFECTIOUS DISEASES, BY REGION 2019–2032 (USD MILLION) 47
TABLE 13 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR CARDIOVASCULAR DISEASE, BY REGION 2019–2032(USD MILLION) 47
TABLE 14 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR NEUROLOGY, BY REGION 2019–2032(USD MILLION) 47
TABLE 15 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR AUTOIMMUNE DISORDERS, BY REGION 2019–2032(USD MILLION) 48
TABLE 16 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR OTHERS, BY REGION 2019–2032(USD MILLION) 48
TABLE 17 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY END USER, 2019–2032(USD MILLION) 50
TABLE 18 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION 2019–2032 (USD MILLION) 51
TABLE 19 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION 2019–2032 (USD MILLION) 52
TABLE 20 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION 2019–2032 (USD MILLION) 52
TABLE 21 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION 2019–2032 (USD MILLION) 53
TABLE 22 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR OTHERS, BY REGION 2019–2032 (USD MILLION) 53
TABLE 23 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2030 (USD MILLION) 55
TABLE 24 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 56
TABLE 25 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 56
TABLE 26 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 57
TABLE 27 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 59
TABLE 28 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 60
TABLE 29 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 60
TABLE 30 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 61
TABLE 31 US LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 61
TABLE 32 US LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 62
TABLE 33 US LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 62
TABLE 34 CANADA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 63
TABLE 35 CANADA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 63
TABLE 36 CANADA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 64
TABLE 37 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 67
TABLE 38 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 68
TABLE 39 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 68
TABLE 40 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 69
TABLE 41 GERMANY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 69
TABLE 42 GERMANY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 70
TABLE 43 GERMANY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 70
TABLE 44 FRANCE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 71
TABLE 45 FRANCE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 71
TABLE 46 FRANCE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 72
TABLE 47 UK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 72
TABLE 48 UK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 73
TABLE 49 UK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 73
TABLE 50 ITALY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 74
TABLE 51 ITALY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 74
TABLE 52 ITALY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 75
TABLE 53 SPAIN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 75
TABLE 54 SPAIN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 76
TABLE 55 SPAIN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 76
TABLE 56 SWITZERLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 77
TABLE 57 SWITZERLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 77
TABLE 58 SWITZERLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 78
TABLE 59 NETHERLANDS: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 78
TABLE 60 NETHERLANDS: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 79
TABLE 61 NETHERLANDS: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 79
TABLE 62 BELGIUM: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 80
TABLE 63 BELGIUM: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 80
TABLE 64 BELGIUM: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 81
TABLE 65 SWEDEN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 81
TABLE 66 SWEDEN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 82
TABLE 67 SWEDEN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 82
TABLE 68 NORWAY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 83
TABLE 69 NORWAY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 83
TABLE 70 NORWAY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 84
TABLE 71 DENMARK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 84
TABLE 72 DENMARK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 85
TABLE 73 DENMARK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 85
TABLE 74 IRELAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 86
TABLE 75 IRELAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 86
TABLE 76 IRELAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 87
TABLE 77 FINLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 87
TABLE 78 FINLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 88
TABLE 79 FINLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 88
TABLE 80 REST OF EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 89
TABLE 81 REST OF EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 89
TABLE 82 REST OF EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 90
TABLE 83 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 93
TABLE 84 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 93
TABLE 85 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 94
TABLE 86 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 94
TABLE 87 CHINA 95
TABLE 88 CHINA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 95
TABLE 89 CHINA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 96
TABLE 90 INDIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 96
TABLE 91 INDIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 97
TABLE 92 INDIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 97
TABLE 93 JAPAN LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 98
TABLE 94 JAPAN LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 98
TABLE 95 JAPAN LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 99
TABLE 96 SOUTH KOREA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 99
TABLE 97 SOUTH KOREA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 100
TABLE 98 SOUTH KOREA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 100
TABLE 99 AUSTRALIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 101
TABLE 100 AUSTRALIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 101
TABLE 101 AUSTRALIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 102
TABLE 102 REST OF ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 102
TABLE 103 REST OF ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 103
TABLE 104 REST OF ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 103
TABLE 105 MAJOR PLAYERS IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 105
TABLE 106 TOP 10 PHARMA COMPANIES FOR LARGE MOLECULE BIOANALYSIS 106
TABLE 107 TOP 10 CDMO COMPANIES FOR LARGE MOLECULE BIOANALYSIS 107
TABLE 108 TOP 10 CRO COMPANIES FOR LARGE MOLECULE BIOANALYSIS 107
TABLE 109 TOP 10 ACADEMIC AND RESEARCH INSTITUTIONS FOR LARGE MOLECULE BIOANALYSIS 108
TABLE 110 MOST ACTIVE PLAYER IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 109
TABLE 111 EXPANSION 110
TABLE 112 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 113
TABLE 113 LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY DEVELOPMENTS 114
TABLE 114 PPD INC: SERVICES OFFERED 115
TABLE 115 PPD INC: KEY DEVELOPMENTS 115
TABLE 116 EUROFINS SCIENTIFIC: SERVICES OFFERED 118
TABLE 117 WUXI APPTEC: SERVICES OFFERED 122
TABLE 118 QPS HOLDINGS: SERVICES OFFERED 123
TABLE 119 QPS HOLDINGS: KEY DEVELOPMENTS 123
TABLE 120 BIOTECHNE: SERVICES OFFERED 126
TABLE 121 ICON PLC: SERVICES OFFERED 129
TABLE 122 CHARLES RIVER LABORATORIES: SERVICES OFFERED 133
TABLE 123 SGS SOCIETE GENRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED 136
TABLE 124 BIOAGILYTIX LABS: SERVICES OFFERED 137
TABLE 125 SMITHERS: SERVICES OFFERED 138
TABLE 126 MESO SCALE DIAGNOSTIC, LLC: SERVICES OFFERED 139
TABLE 127 CMIC HOLDINGS CO., LTD: SERVICES OFFERED 141

 

　

ページTOPに戻る


　

Summary

North America, Europe, and Asia-Pacific Large Molecule Bioanalysis Testing Services Market Research Report Forecast to 2030
Market Overview
The market for large molecule bioanalysis testing services in North America, Europe, and Asia-Pacific is expanding due to rising demand for high-tech and dependable large molecule bioanalytical testing services, a growing trend of outsourcing laboratory testing services, and an increase in the number of clinical trials. However, the difficulties in developing appropriate analytical techniques are limiting the growth of the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market. Furthermore, the growing prevalence of chronic diseases is expected to provide lucrative growth opportunities for the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market.
The concentration of large molecules in biological samples such as proteins and antibodies is determined using large molecule bioanalytical testing services. Large molecules are frequently utilized in drug development, and bioanalytical testing is required to ensure these drugs' safety and efficacy.
The expected growth in market can be attributed to the increasing demand for high-tech and reliable large molecule bioanalytical testing services, growing trend of outsourcing laboratory testing services, and rising R&D expenditure in the biopharmaceutical sector. However, the market is also held back by challenges in the development of proper analytical techniques. Nevertheless, it is anticipated that the growing incidence of chronic diseases will create lucrative opportunities for the players operating in the North America, Europe, And Asia-Pacific large molecule bioanalysis testing services market.
Market Segmentation
Based on test type, the large molecule bioanalysis testing market has been segmented into pharmacokinetic (PK) studies, pharmacodynamic studies, bioequivalence studies, immunogenicity testing, biomarker testing and others. Based on therapeutic area, the large molecule bioanalysis testing market has been segmented into oncology, infectious diseases, cardiovascular diseases, neurology, autoimmune disorders, and others. Based on test type, the large molecule bioanalysis testing market has been segmented into pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), academic and research institutes, and others.
Regional Analysis
Based on region, the large molecule bioanalysis testing services market has been segmented into North America, Europe, and Asia-Pacific. North America accounted for the largest market share of 45.29% in 2022 and is anticipated to reach approximately USD 1,498.85 million by 2030 at an 8.70% CAGR during the forecast period. However, Asia-Pacific is projected to register the highest CAGR of 11.52% by 2030.
Major Players
Laboratory Corporation of America Holdings (US), ICON plc (Ireland), SGS Société Générale de Surveillance SA (Switzerland), WuXi AppTec (China), and Charles River Laboratories (US). Other key players contributing to the market growth include Eurofins Scientific (luxembourg), QPS Holdings (US), BioTechne (US), PPD, Inc (US), BioAgilytix Labs (US), Smithers (US), Meso Scale Diagnostic, LLC (US), and CMIC HOLDINGS CO., LTD (Japan)




ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 17
1.1 OVERVIEW 17
2 MARKET INTRODUCTION 19
2.1 DEFINITION 19
2.2 SCOPE OF THE STUDY 19
2.3 RESEARCH OBJECTIVE 19
2.4 MARKET STRUCTURE 20
2.5 ASSUMPTIONS & LIMITATIONS 20
3 RESEARCH METHODOLOGY 21
3.1 DATA MINING 21
3.2 SECONDARY RESEARCH 22
3.3 PRIMARY RESEARCH 23
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24
3.5 FORECASTING TECHNIQUES 25
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26
3.6.1 BOTTOM-UP APPROACH 26
3.6.2 TOP-DOWN APPROACH 27
3.7 DATA TRIANGULATION 27
3.8 VALIDATION 28
4 MARKET DYNAMICS 29
4.1 OVERVIEW 29
4.2 DRIVERS 30
4.2.1 INCREASING DEMAND FOR HIGH-TECH AND RELIABLE LARGE MOLECULE BIOANALYTICAL TESTING SERVICES 30
4.2.2 GROWING TREND OF OUTSOURCING LABORATORY TESTING SERVICES 30
4.2.3 RISING R&D EXPENDITURE IN THE BIOPHARMACEUTICAL SECTOR 30
4.3 RESTRAINTS 31
4.3.1 CHALLENGES IN THE DEVELOPMENT OF PROPER ANALYTICAL TECHNIQUES 31
4.4 OPPORTUNITIES 32
4.4.1 GROWING INCIDENCE OF CHRONIC DISEASES 32
5 MARKET FACTOR ANALYSIS 33
5.1 VALUE CHAIN ANALYSIS 33
5.1.1 CUSTOMER ACQUISITION (PRE-PURCHASE QUERY) 33
5.1.2 SERVICE CUSTOMIZATION 34
5.1.3 CUSTOMER PURCHASE SUPPORT 34
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT 34
5.2 PORTER'S FIVE FORCES MODEL 35
5.2.1 THREAT OF NEW ENTRANTS 36
5.2.2 BARGAINING POWER OF SUPPLIERS 36
5.2.3 THREAT OF SUBSTITUTES 36
5.2.4 BARGAINING POWER OF BUYERS 36
5.2.5 INTENSITY OF RIVALRY 36
5.3 IMPACT OF COVID-19 ON THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 37
5.3.1 IMPACT ON SUPPLY CHAIN 37
5.3.2 IMPACT ON SERVICE PROVIDER 37
6 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE 38
6.1 OVERVIEW 38
6.2 PHARMACOKINETIC (PK) STUDIES 40
6.3 PHARMACODYNAMIC (PD) STUDIES 41
6.4 BIOEQUIVALENCE STUDIES 41
6.5 BIOMARKER TESTING 42
6.6 IMMUNOGENICITY TESTING 42
6.7 OTHERS 43
7 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY THERAPEUTIC AREA 44
7.1 OVERVIEW 44
7.2 ONCOLOGY 46
7.3 INFECTIOUS DISEASES 47
7.4 CARDIOVASCULAR DISEASE 47
7.5 NEUROLOGY 47
7.6 AUTOIMMUNE DISORDERS 48
7.7 OTHERS 48
8 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY END USER 49
8.1 OVERVIEW 49
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 51
8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS) 52
8.4 CONTRACT RESEARCH ORGANIZATIONS (CROS) 52
8.5 ACADEMIC AND RESEARCH INSTITUTES 53
8.6 OTHERS 53
9 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY REGION 54
9.1 OVERVIEW 54
9.2 NORTH AMERICA 58
9.2.1 US 61
9.2.2 CANADA 63
9.3 EUROPE 65
9.3.1 GERMANY 69
9.3.2 FRANCE 71
9.3.3 UK 72
9.3.4 ITALY 74
9.3.5 SPAIN 75
9.3.6 SWITZERLAND 77
9.3.7 NETHERLANDS 78
9.3.8 BELGIUM 80
9.3.9 SWEDEN 81
9.3.10 NORWAY 83
9.3.11 DENMARK 84
9.3.12 IRELAND 86
9.3.13 FINLAND 87
9.3.14 REST OF EUROPE 89
9.4 ASIA-PACIFIC 91
9.4.1 CHINA 95
9.4.2 INDIA 96
9.4.3 JAPAN 98
9.4.4 SOUTH KOREA 99
9.4.5 AUSTRALIA 101
9.4.6 REST OF ASIA-PACIFIC 102
10 COMPETITIVE LANDSCAPE 104
10.1 OVERVIEW 104
10.2 COMPETITIVE BENCHMARKING 106
10.3 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CATEGORY 106
10.3.1 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY PHARMA 106
10.3.2 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CDMO 107
10.3.3 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CRO 107
10.3.4 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY ACADEMIC AND RESEARCH INSTITUTIONS 108
10.4 MAJOR GROWTH STRATEGY IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 108
10.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 109
10.6 KEY DEVELOPMENT ANALYSIS 110
10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 110
10.7.1 EXPANSION 110
10.8 MAJOR PLAYERS FINANCIAL 111
10.8.1 SALES (USD MILLION), 2022 111
10.8.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022 111
11 COMPANY PROFILES 112
11.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 112
11.1.1 COMPANY OVERVIEW 112
11.1.2 FINANCIAL OVERVIEW 113
11.1.3 SERVICES OFFERED 113
11.1.4 KEY DEVELOPMENTS 114
11.1.5 SWOT ANALYSIS 114
11.1.6 KEY STRATEGIES 114
11.2 PPD INC 115
11.2.1 COMPANY OVERVIEW 115
11.2.2 FINANCIAL OVERVIEW 115
11.2.3 SERVICES OFFERED 115
11.2.4 KEY DEVELOPMENTS 115
11.2.5 SWOT ANALYSIS 116
11.2.6 KEY STRATEGIES 116
11.3 EUROFINS SCIENTIFIC 117
11.3.1 COMPANY OVERVIEWS 117
11.3.2 FINANCIAL OVERVIEW 118
11.3.3 SERVICES OFFERED 118
11.3.4 KEY DEVELOPMENTS 119
11.3.5 SWOT ANALYSIS 119
11.3.6 KEY STRATEGIES 119
11.4 WUXI APPTEC 120
11.4.1 COMPANY OVERVIEW 120
11.4.2 FINANCIAL OVERVIEW 121
11.4.3 SERVICES OFFERED 122
11.4.4 KEY DEVELOPMENTS 122
11.4.5 KEY STRATEGIES 122
11.5 QPS HOLDINGS 123
11.5.1 COMPANY OVERVIEW 123
11.5.2 FINANCIAL OVERVIEW 123
11.5.3 SERVICES OFFERED 123
11.5.4 KEY DEVELOPMENTS 123
11.5.5 KEY STRATEGIES 123
11.6 BIO-TECHNE 125
11.6.1 COMPANY OVERVIEW 125
11.6.2 FINANCIAL OVERVIEW 126
11.6.3 SERVICES OFFERED 126
11.6.4 KEY DEVELOPMENTS 127
11.6.5 KEY STRATEGIES 127
11.7 ICON PLC 128
11.7.1 COMPANY OVERVIEW 128
11.7.2 FINANCIAL OVERVIEW 129
11.7.3 SERVICES OFFERED 129
11.7.4 KEY DEVELOPMENTS 129
11.7.5 SWOT ANALYSIS 130
11.7.6 KEY STRATEGIES 130
11.8 CHARLES RIVER LABORATORIES 131
11.8.1 COMPANY OVERVIEW 131
11.8.2 FINANCIAL OVERVIEW 132
11.8.3 SERVICES OFFERED 133
11.8.4 KEY DEVELOPMENTS 133
11.8.5 SWOT ANALYSIS 134
11.8.6 KEY STRATEGIES 134
11.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA 135
11.9.1 COMPANY OVERVIEW 135
11.9.2 FINANCIAL OVERVIEW 135
11.9.3 PRODUCTS/SERVICES OFFERED 136
11.9.4 KEY DEVELOPMENTS 136
11.9.5 KEY STRATEGIES 136
11.10 BIOAGILYTIX LABS 137
11.10.1 COMPANY OVERVIEW 137
11.10.2 FINANCIAL OVERVIEW 137
11.10.3 SERVICES OFFERED 137
11.10.4 KEY DEVELOPMENTS 137
11.10.5 KEY STRATEGIES 137
11.11 SMITHERS 138
11.11.1 COMPANY OVERVIEW 138
11.11.2 FINANCIAL ANALYSIS 138
11.11.3 SERVICES OFFERED 138
11.11.4 KEY DEVELOPMENTS 138
11.11.5 KEY STRATEGIES 138
11.12 MESO SCALE DIAGNOSTICS, LLC 139
11.12.1 COMPANY OVERVIEW 139
11.12.2 FINANCIAL ANALYSIS 139
11.12.3 SERVICES OFFERED 139
11.12.4 KEY DEVELOPMENTS 139
11.12.5 KEY STRATEGIES 139
11.13 CMIC HOLDINGS CO., LTD 140
11.13.1 COMPANY OVERVIEW 140
11.13.2 FINANCIAL OVERVIEW 140
11.13.3 SERVICES OFFERED 141
11.13.4 KEY DEVELOPMENTS 141
11.13.5 KEY STRATEGIES 141
12 REFERENCES 142
12.1 RELATED REPORTS 143

ページTOPに戻る



List of Tables/Graphs

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 20
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23
TABLE 3 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2032 (USD MILLION) 39
TABLE 4 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR PHARMACOKINETIC (PK) STUDIES, BY REGION 2019–2032 (USD MILLION) 40
TABLE 5 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR PHARMACODYNAMIC (PD) STUDIES, BY REGION 2019–2032 (USD MILLION) 41
TABLE 6 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR BIOEQUIVALENCE STUDIES, BY REGION 2019–2032 (USD MILLION) 41
TABLE 7 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR BIOMARKER TESTING, BY REGION 2019–2032 (USD MILLION) 42
TABLE 8 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR IMMUNOGENICITY TESTING, BY REGION 2019–2032 (USD MILLION) 42
TABLE 9 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR OTHERS, BY REGION 2019–2032 (USD MILLION) 43
TABLE 10 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2032 (USD MILLION) 45
TABLE 11 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR ONCOLOGY, BY REGION 2019–2032 (USD MILLION) 46
TABLE 12 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR INFECTIOUS DISEASES, BY REGION 2019–2032 (USD MILLION) 47
TABLE 13 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR CARDIOVASCULAR DISEASE, BY REGION 2019–2032(USD MILLION) 47
TABLE 14 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR NEUROLOGY, BY REGION 2019–2032(USD MILLION) 47
TABLE 15 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR AUTOIMMUNE DISORDERS, BY REGION 2019–2032(USD MILLION) 48
TABLE 16 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR OTHERS, BY REGION 2019–2032(USD MILLION) 48
TABLE 17 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY END USER, 2019–2032(USD MILLION) 50
TABLE 18 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION 2019–2032 (USD MILLION) 51
TABLE 19 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION 2019–2032 (USD MILLION) 52
TABLE 20 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION 2019–2032 (USD MILLION) 52
TABLE 21 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION 2019–2032 (USD MILLION) 53
TABLE 22 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, FOR OTHERS, BY REGION 2019–2032 (USD MILLION) 53
TABLE 23 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2030 (USD MILLION) 55
TABLE 24 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 56
TABLE 25 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 56
TABLE 26 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 57
TABLE 27 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 59
TABLE 28 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 60
TABLE 29 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 60
TABLE 30 NORTH AMERICA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 61
TABLE 31 US LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 61
TABLE 32 US LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 62
TABLE 33 US LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 62
TABLE 34 CANADA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 63
TABLE 35 CANADA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 63
TABLE 36 CANADA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 64
TABLE 37 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 67
TABLE 38 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 68
TABLE 39 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 68
TABLE 40 EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 69
TABLE 41 GERMANY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 69
TABLE 42 GERMANY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 70
TABLE 43 GERMANY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 70
TABLE 44 FRANCE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 71
TABLE 45 FRANCE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 71
TABLE 46 FRANCE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 72
TABLE 47 UK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 72
TABLE 48 UK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 73
TABLE 49 UK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 73
TABLE 50 ITALY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 74
TABLE 51 ITALY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 74
TABLE 52 ITALY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 75
TABLE 53 SPAIN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 75
TABLE 54 SPAIN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 76
TABLE 55 SPAIN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 76
TABLE 56 SWITZERLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 77
TABLE 57 SWITZERLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 77
TABLE 58 SWITZERLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 78
TABLE 59 NETHERLANDS: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 78
TABLE 60 NETHERLANDS: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 79
TABLE 61 NETHERLANDS: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 79
TABLE 62 BELGIUM: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 80
TABLE 63 BELGIUM: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 80
TABLE 64 BELGIUM: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 81
TABLE 65 SWEDEN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 81
TABLE 66 SWEDEN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 82
TABLE 67 SWEDEN: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 82
TABLE 68 NORWAY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 83
TABLE 69 NORWAY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 83
TABLE 70 NORWAY: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 84
TABLE 71 DENMARK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 84
TABLE 72 DENMARK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 85
TABLE 73 DENMARK: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 85
TABLE 74 IRELAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 86
TABLE 75 IRELAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 86
TABLE 76 IRELAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 87
TABLE 77 FINLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 87
TABLE 78 FINLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 88
TABLE 79 FINLAND: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 88
TABLE 80 REST OF EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 89
TABLE 81 REST OF EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY THERAPEUTIC AREA, 2019–2030 (USD MILLION) 89
TABLE 82 REST OF EUROPE: LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET BY END USER, 2019–2030 (USD MILLION) 90
TABLE 83 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2030 (USD MILLION) 93
TABLE 84 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 93
TABLE 85 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 94
TABLE 86 ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 94
TABLE 87 CHINA 95
TABLE 88 CHINA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 95
TABLE 89 CHINA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 96
TABLE 90 INDIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 96
TABLE 91 INDIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 97
TABLE 92 INDIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 97
TABLE 93 JAPAN LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 98
TABLE 94 JAPAN LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 98
TABLE 95 JAPAN LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 99
TABLE 96 SOUTH KOREA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 99
TABLE 97 SOUTH KOREA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 100
TABLE 98 SOUTH KOREA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 100
TABLE 99 AUSTRALIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 101
TABLE 100 AUSTRALIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 101
TABLE 101 AUSTRALIA LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 102
TABLE 102 REST OF ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY TEST TYPE, 2019–2030 (USD MILLION) 102
TABLE 103 REST OF ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2030 (USD MILLION) 103
TABLE 104 REST OF ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION) 103
TABLE 105 MAJOR PLAYERS IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 105
TABLE 106 TOP 10 PHARMA COMPANIES FOR LARGE MOLECULE BIOANALYSIS 106
TABLE 107 TOP 10 CDMO COMPANIES FOR LARGE MOLECULE BIOANALYSIS 107
TABLE 108 TOP 10 CRO COMPANIES FOR LARGE MOLECULE BIOANALYSIS 107
TABLE 109 TOP 10 ACADEMIC AND RESEARCH INSTITUTIONS FOR LARGE MOLECULE BIOANALYSIS 108
TABLE 110 MOST ACTIVE PLAYER IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET 109
TABLE 111 EXPANSION 110
TABLE 112 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 113
TABLE 113 LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY DEVELOPMENTS 114
TABLE 114 PPD INC: SERVICES OFFERED 115
TABLE 115 PPD INC: KEY DEVELOPMENTS 115
TABLE 116 EUROFINS SCIENTIFIC: SERVICES OFFERED 118
TABLE 117 WUXI APPTEC: SERVICES OFFERED 122
TABLE 118 QPS HOLDINGS: SERVICES OFFERED 123
TABLE 119 QPS HOLDINGS: KEY DEVELOPMENTS 123
TABLE 120 BIOTECHNE: SERVICES OFFERED 126
TABLE 121 ICON PLC: SERVICES OFFERED 129
TABLE 122 CHARLES RIVER LABORATORIES: SERVICES OFFERED 133
TABLE 123 SGS SOCIETE GENRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED 136
TABLE 124 BIOAGILYTIX LABS: SERVICES OFFERED 137
TABLE 125 SMITHERS: SERVICES OFFERED 138
TABLE 126 MESO SCALE DIAGNOSTIC, LLC: SERVICES OFFERED 139
TABLE 127 CMIC HOLDINGS CO., LTD: SERVICES OFFERED 141

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Market Research Future社のライフサイエンス分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Market Research Future社はどのような調査会社ですか?


マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。   下記分野については、分野毎に専... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20　10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.